Creative Medical Technology Holdings Inc

Creative Medical Technology Holdings Inc

CELZ · NASDAQ · Healthcare / Biotechnology

0.5281USD-0.09 (-14.35%)

Price History

Full chart

Market Stats

Previous Close0.6166
Open0.615
Day Range0.5281 – 0.6226
52-Week Range0.62 – 6.25
Volume152.68K
Market Cap6.39M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.04
Dividend Yield0.00%
Beta2.04
50-Day Avg0.9976
200-Day Avg1.74

About

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Company Details

Leadership

  • Mr. Timothy WarbingtonCo-Founder, Chairman, President & CEO · b. 1962
  • Mr. Donald F. Dickerson MBASenior VP, CFO & Director · b. 1965

Financials

Income Statement

Currency: USD2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--------0004.80K124.40K165.50K164.50K87.75K88.60K9.00K11.00K6.00K
Growth (%)------------+2491.67%+33.04%-0.60%-46.65%+0.96%-89.84%+22.22%-45.45%
Cost of Revenue--------00766.07K8.00K70.38K45.50K50.60K47.95K28.49K3.60K4.40K2.19K
Gross Profit--------00-766.07K-3.20K54.02K120.00K113.90K39.80K60.11K5.40K6.60K3.81K
Gross Margin------------66.67%43.43%72.51%69.24%45.36%67.84%60.00%60.00%63.43%
Operating Expense--------19.43K20.83K01.17M1.17M1.25M1.23M3.17M10.30M5.63M5.75M6.15M
Operating Income-1.43K-13.62K-53.49K-30.55K-14.29K-19.83K-20.10K-20.12K-19.43K-20.83K-766.07K-1.18M-1.11M-1.13M-1.11M-3.13M-10.24M-5.62M-5.74M-6.14M
Operating Margin------------24537.63%-895.68%-682.88%-677.71%-3562.17%-11562.50%-62445.91%-52216.92%-102380.23%
EBITDA-1.43K-13.62K-53.49K-30.55K-14.29K-19.83K-20.10K-20.12K-19.43K-20.83K-750.32K-1.16M-1.09M-6.56M-35.03M23.58M-10.05M-5.19M-5.38M-6.02M
EBITDA Margin------------24204.40%-878.68%-3964.47%-21294.13%26873.17%-11345.33%-57688.78%-48936.63%-100324.78%
Net Income1.37K-9.54K-52.64K-31.61K-17.26K-24.05K-25.59K-27.28K-28.01K-30.76K-766.07K-2.66M-13.66M-8.48M-36.33M19.21M-10.14M-5.29M-5.49M-6.00M
Net Income Margin------------55398.08%-10977.21%-5126.09%-22082.21%21892.75%-11449.26%-58739.71%-49940.74%-99916.80%
R&D--------85.33K85.33K85.33K260.08K96.62K00109.18K6.27M1.97M2.40M2.26M
R&D as % of Total Revenue-----------5418.44%77.67%0.00%0.00%124.42%7075.46%21895.99%21825.25%37663.27%
Interest Expense---1.06K2.97K4.22K5.49K7.16K8.59K9.93K6.40K377.59K1.36M1.90M1.23M4.28M100.33K---
Interest Expense % of Total Revenue-----------7866.40%1094.39%1145.33%747.47%4875.48%113.24%---

Balance Sheet

Currency: USD2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets29.34K35.63K1.50K3.08K4143.10K1.57K374954216322.51K203.15K477.16K530.80K717.77K11.27M19.19M10.72M6.67M7.81M
Total Liabilities8.45K9.28K74533.93K48.52K75.27K99.32K125.41K154.00K184.02K480.30K2.44M4.47M8.60M40.52M1.05M3.32M371.39K327.64K284.88K
Total Equity20.89K26.35K757-30.85K-48.11K-72.16K-97.75K-125.03K-153.04K-183.80K-157.79K-2.24M-3.99M-8.07M-39.80M10.22M15.86M10.34M6.34M7.51M
Cash-21.77K3175754141.10K781374954216221.87K13.70K304.06K88.65K98.01K10.72M8.32M3.47M5.94M7.21M
Total Debt---32.06K50.00K70.00K90.00K120.00K143.81K166.94K125.00K513.46K682.06K1.06M788.70K14.19K14.19K14.19K14.19K14.19K
Net Debt--21.77K-31731.48K49.59K68.89K89.22K119.63K142.85K166.72K-96.87K499.77K378.00K973.62K690.69K-10.72M-8.32M-3.47M-5.94M-7.19M

Cash Flow

Currency: USD2006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow1.14K-12.86K-57.16K-30.74K-13.66K-13.96K-16.77K-22.91K-17.32K-14.64K-445.23K-889.62K-1.05M-1.21M-434.56K-2.22M-7.80M-8.03M-5.30M-5.86M
Investing Cash Flow-23.75K19.63K8.67K------10.00K-10.00K-10.00K-250.00K-250.00K-250.00K-250.00K--10.08M3.45M6.32M-50.50K
Financing Cash Flow1.00K15.00K27.05K31.00K13.50K14.65K16.45K22.50K17.90K13.90K677.00K681.45K1.34M997.68K693.92K12.84M15.47M-270.95K1.45M7.17M
Capital Expenditure000000000010.00K003250.00K04100.00K200.00K5
Free Cash Flow1.14K-12.86K-57.16K-30.74K-13.66K-13.96K-16.77K-22.91K-17.32K-14.64K-455.23K-889.62K-1.05M-1.21M-684.56K-2.22M-7.80M-8.13M-5.30M-5.86M
Dividends Paid---------------4.78M----
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%102.25%100.00%100.00%100.00%157.53%100.00%100.00%101.25%100.00%100.00%
Dividend Paid to FCF----------------215.94%----

Earnings

Report DateMar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Nov 13, 2020Mar 17, 2021May 17, 2021Aug 16, 2021Dec 6, 2021Mar 30, 2022May 13, 2022Aug 12, 2022Nov 10, 2022Mar 31, 2023May 12, 2023Aug 11, 2023Nov 14, 2023Mar 22, 2024May 10, 2024Aug 9, 2024Nov 8, 2024Mar 20, 2025May 9, 2025Aug 8, 2025Nov 7, 2025Feb 25, 2026May 8, 2026Aug 7, 2026Nov 6, 2026
EPS Estimate-------------------------0.23-2.30-1.50-1.30-0.07-1.00-0.83-0.86-1.13-1.15-0.84-0.85-0.63-0.52-0.63-0.48-0.37-0.39-0.39-0.24
EPS Actual-0.30-0.33-0.32-0.28-0.35-1.25-0.07-2.06-6.05-1.55-0.32184.54-61.93-6.22-119.36-146.512.44-5.450.160.14-31.9311.18-1.25-0.75-4.16-1.80-2.00-0.70-0.07-0.70-0.78-1.02-1.19-0.73-1.11-0.75-1.12-0.83-0.48-0.48-0.80-0.38-0.41-
Surprise-------------------------1708.70%21.74%-33.33%46.15%0.00%30.00%6.02%-18.60%-5.31%36.52%-32.14%11.76%-77.78%-59.62%23.81%0.00%-116.22%2.56%-5.13%-
Timing-----------------------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hours--

Key Statistics & Ratios

Market Cap6.39M
Enterprise Value-2.64M
Trailing P/E0.00
Forward P/E0.00
Price / Sales2131.59
Price / Book0.71
EPS-2.04
Book Value1.33
Revenue (TTM)3.00K
Gross Profit (TTM)2.01K
EBITDA-6.13M
Profit Margin0.00%
Operating Margin-208004.40%
Return on Equity-77.88%
Return on Assets-47.32%
Shares Outstanding6.59M
Shares Float6.56M
Beta2.04
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 1 analystsTarget 20.00
  • Buy
    1

Ownership Breakdown

Institutions
5.66%
Insiders
0.53%
Retail / Other
93.81%

Top Institutional Holders

  • Hudson Bay Capital Management LP
    135.17K2.05%
  • Anson Funds Management LP
    105.55K1.60%
  • Geode Capital Management, LLC
    38.29K0.58%
  • Vanguard Capital Management, LLC
    20.35K0.31%
  • XTX Topco Ltd
    14.26K0.22%
  • Susquehanna International Group, LLP
    10.47K0.16%
  • Vanguard Fiduciary Trust Co
    5.52K0.08%
  • Wells Fargo & Co
    5.00K0.08%
  • Global Retirement Partners, LLC.
    4.12K0.06%
  • Tower Research Capital LLC
    2.09K0.03%
  • Morgan Stanley - Brokerage Accounts
    5340.01%
  • FMR Inc
    2500.00%
  • TD Waterhouse Canada Inc
    00.00%
  • Citadel Advisors Llc
    00.00%
  • Advisor Group Holdings, Inc.
    00.00%
  • Bank of America Corp
    00.00%
  • UBS Group AG
    10.00%

Top Fund Holders

  • Fidelity Extended Market Index
    18.78K0.28%
  • Fidelity Series Total Market Index
    3.97K0.06%
  • Fidelity Total Market Index
    1.55K0.02%

Stock Splits

  • Jun 12, 20231:10
  • Nov 10, 20211:500
  • Feb 3, 20201:150